• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Trifluridine/tipiracil plus ramucirumab in gastric cancer.曲氟尿苷/替匹嘧啶联合雷莫西尤单抗治疗胃癌
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):154-155. doi: 10.1016/S2468-1253(21)00013-3. Epub 2021 Jan 26.
2
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.替氟尿苷/盐酸替匹嘧啶与雷莫芦单抗治疗既往治疗的晚期胃癌的安全性和活性：一项开放标签、单臂、Ⅱ期临床试验。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):209-217. doi: 10.1016/S2468-1253(20)30396-4. Epub 2021 Jan 26.
3
Trifluridine/tipiracil with and without ramucirumab for advanced gastric cancer: a comparative observational study.曲氟尿苷替匹嘧啶联合或不联合雷莫芦单抗治疗晚期胃癌：一项比较观察性研究。
Sci Rep. 2024 Jun 3;14(1):12658. doi: 10.1038/s41598-024-61975-7.
4
Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.一项评估替氟尿苷/盐酸拓扑替康联合雷莫芦单抗作为三线或后线治疗晚期胃癌的疗效和安全性的 II 期研究方案。
Nagoya J Med Sci. 2024 Feb;86(1):43-51. doi: 10.18999/nagjms.86.1.43.
5
Effects of prior therapies on outcomes with trifluridine/tipiracil in patients with metastatic gastric/gastroesophageal junction cancer in a randomized phase III trial (TAGS).在一项随机 III 期试验（TAGS）中，先前治疗对转移性胃/胃食管结合部癌患者接受曲氟尿苷/替匹嘧啶治疗结局的影响。
J Cancer Res Clin Oncol. 2023 Sep;149(11):9361-9374. doi: 10.1007/s00432-023-04813-z. Epub 2023 May 22.
6
Trifluridine/tipiracil for the treatment of metastatic gastric cancer.替氟尿苷/替匹嘧啶用于转移性胃癌的治疗。
Expert Rev Gastroenterol Hepatol. 2020 Feb;14(2):65-70. doi: 10.1080/17474124.2020.1715209. Epub 2020 Jan 14.
7
Trifluridine/tipiracil versus placebo in patients with heavily pretreated metastatic gastric cancer (TAGS): a randomised, double-blind, placebo-controlled, phase 3 trial.替氟尿苷/替匹嘧啶对比安慰剂用于既往大量治疗的转移性胃癌患者（TAGS）：一项随机、双盲、安慰剂对照的 3 期临床试验。
Lancet Oncol. 2018 Nov;19(11):1437-1448. doi: 10.1016/S1470-2045(18)30739-3. Epub 2018 Oct 21.
8
Trifluridine/Tipiracil in heavily pretreated metastatic gastric cancer. A perspective based on pharmacological costs.三氟尿苷/替匹嘧啶用于预处理严重的转移性胃癌。基于药物成本的视角。
Eur J Cancer. 2020 Oct;138:77-79. doi: 10.1016/j.ejca.2020.07.032. Epub 2020 Aug 29.
9
[Long-Term Survivor with Recurrent Gastric Cancer Using Trifluridine/Tipiracil as a Late-Line Chemotherapy].[使用曲氟尿苷/替匹嘧啶作为晚期化疗方案的复发性胃癌长期存活者]
Gan To Kagaku Ryoho. 2020 Dec;47(13):2056-2058.
10
Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.替氟尿苷/替匹嘧啶对比纳武利尤单抗治疗日本晚期转移性胃癌的成本效果分析。
Jpn J Clin Oncol. 2021 Aug 30;51(9):1383-1390. doi: 10.1093/jjco/hyab086.

引用本文的文献

1
Rapidly Evolving Treatment Landscape for Metastatic Esophagogastric Carcinoma: Review of Recent Data.转移性食管胃癌快速演变的治疗格局：近期数据综述
Onco Targets Ther. 2021 Aug 5;14:4361-4381. doi: 10.2147/OTT.S216047. eCollection 2021.

本文引用的文献

1
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for patients with advanced or metastatic gastroesophageal adenocarcinoma with or without prior docetaxel - results from the phase II RAMIRIS Study of the German Gastric Cancer Study Group at AIO.FOLFIRI联合雷莫西尤单抗对比紫杉醇联合雷莫西尤单抗作为晚期或转移性胃食管腺癌患者的二线治疗（无论是否接受过多西他赛治疗）——德国胃癌研究组AIO的II期RAMIRIS研究结果
Eur J Cancer. 2022 Apr;165:48-57. doi: 10.1016/j.ejca.2022.01.015. Epub 2022 Feb 21.
2
Safety and activity of trifluridine/tipiracil and ramucirumab in previously treated advanced gastric cancer: an open-label, single-arm, phase 2 trial.替氟尿苷/盐酸替匹嘧啶与雷莫芦单抗治疗既往治疗的晚期胃癌的安全性和活性：一项开放标签、单臂、Ⅱ期临床试验。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):209-217. doi: 10.1016/S2468-1253(20)30396-4. Epub 2021 Jan 26.
3
Treatment after progression in the era of immunotherapy.免疫治疗时代的进展后治疗。
Lancet Oncol. 2020 Oct;21(10):e463-e476. doi: 10.1016/S1470-2045(20)30328-4.
4
PD-1 regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer.PD-1 阻断扩增的 PD-1 调节性 T 细胞促进癌症的过度进展。
Proc Natl Acad Sci U S A. 2019 May 14;116(20):9999-10008. doi: 10.1073/pnas.1822001116. Epub 2019 Apr 26.
5
Initial Report of Second-Line FOLFIRI in Combination with Ramucirumab in Advanced Gastroesophageal Adenocarcinomas: A Multi-Institutional Retrospective Analysis.二线 FOLFIRI 联合雷莫芦单抗治疗晚期胃食管腺癌的初步报告：多机构回顾性分析。
Oncologist. 2019 Apr;24(4):475-482. doi: 10.1634/theoncologist.2018-0602. Epub 2018 Nov 23.
6
Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment.雷莫芦单抗靶向 VEGFR2 强烈影响肿瘤微环境中的效应器/激活调节性 T 细胞和 CD8 T 细胞。
J Immunother Cancer. 2018 Oct 11;6(1):106. doi: 10.1186/s40425-018-0403-1.
7
Subgroup analyses of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomized clinical trial in second-line treatment of gastric cancer.RAINBOW研究中雷莫西尤单抗在日本和西方患者中的安全性和疗效亚组分析：一项胃癌二线治疗的随机临床试验
Gastric Cancer. 2016 Jul;19(3):927-38. doi: 10.1007/s10120-015-0559-z. Epub 2015 Oct 28.

Trifluridine/tipiracil plus ramucirumab in gastric cancer.

作者信息

Zhu Mojun, Sonbol Mohamad Bassam, Yoon Harry H

机构信息

Mayo Clinic, Rochester, MN 55905, USA.

Mayo Clinic, Phoenix, AZ, USA.

出版信息

Lancet Gastroenterol Hepatol. 2021 Mar;6(3):154-155. doi: 10.1016/S2468-1253(21)00013-3. Epub 2021 Jan 26.

DOI:10.1016/S2468-1253(21)00013-3
PMID:33508243
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8447873/
Abstract
摘要